reference/14869873

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/14869873

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, Non-U.S. Gov't
endingPage	205
issn	1573-0646 0167-6997
issueIdentifier	2
pageRange	195-205
publicationName	Investigational New Drugs
startingPage	195
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_a9ba4b9227cc35b5588ed5c48c0aec2d http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_a1d87a6c3b25210f0fba35c4abf5159b http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_d57d377d48d64369e8ba89ca6f835619 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_e67f9519a4f0833c9fe87cf3db7148a9
bibliographicCitation	Park SE, Kim HG, Kim DE, Jung YJ, Kim Y, Jeong SY, Choi EK, Hwang JJ, Kim CS. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer. Invest New Drugs. 2018 Apr;36(2):195–205. doi: 10.1007/s10637-017-0529-x. PMID: 29110173.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7982b2538521391002b37b35432bf1be http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_867989f20241037fcbbfcb32c8cbb310 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0f081995e3318628c719bc299cec07d1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_355c4e9066fb9a5b3826d76a94cb457f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9353737e9e0e4f65c94edf5b88abc713 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_51744b19bb6b06ba6713d765b885f336 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_224e6e241c3aa0f2025a01a8199e64c0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ab563ec24b43689f711406285899082b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_689a7dda609997f40cb14f29f82958b6
date	2017-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1007/s10637-017-0529-x https://pubmed.ncbi.nlm.nih.gov/29110173
isPartOf	https://portal.issn.org/resource/ISSN/0167-6997 https://portal.issn.org/resource/ISSN/1573-0646 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/4372
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/ https://scigraph.springernature.com/
title	Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer
discusses	http://id.nlm.nih.gov/mesh/M0574267 http://id.nlm.nih.gov/mesh/M0010739 http://id.nlm.nih.gov/mesh/M0022142 http://id.nlm.nih.gov/mesh/M0014459 http://id.nlm.nih.gov/mesh/M0184558 http://id.nlm.nih.gov/mesh/M0288128 http://id.nlm.nih.gov/mesh/M0527853 http://id.nlm.nih.gov/mesh/M0018556
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_3.4.21.77 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_819486118bb9f4a902acbc5eae73587c http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5311 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_d445950097f904f6fd5b28f1b37c3abf http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fce276cc0efd2412c7dafdbb1e82fcc8 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_4f3366af2ce1555e259faab86aad3bef http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16117309 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_56bca13690bbda77dabb7ce558af711e http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9476 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_3.5.1.98 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_c582dec943ff7b743aa0691df291cea6

Total number of triples: 55.